Completed PHASE2 INTERVENTIONAL 2-arm NCT00136474

Amifostine for Head and Neck Irradiation in Lymphoma

A Randomized Phase II Trial of Amifostine for Head and Neck Irradiation in Lymphoma

Sponsor: Beth Israel Deaconess Medical Center

Conditions Hodgkin's Disease Lymphoma Non-Hodgkin's Lymphoma

Interventions Amifostine Radiation Therapy

Updated 7 times since 2017 Last updated: Oct 30, 2009 Started: May 31, 2003 Primary completion: May 31, 2005 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hodgkin's Disease and Lymphoma, this trial is completed. The trial is conducted by Beth Israel Deaconess Medical Center and has accumulated 7 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Dana-Farber Cancer Institute
MedImmune LLC

Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States